Cidara Therapeutics Appoints James Levine as CFO and Jessica Oien as General Counsel and Secretary
December 03 2018 - 8:00AM
Business Wire
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology
company developing novel anti-infectives including immunotherapies,
today announced the appointments of James (Jamie) Levine as chief
financial officer and Jessica Oien, J.D., as general counsel and
secretary.
“We are extremely pleased to welcome Jamie and Jessica to our
executive management team. They both have deep, highly relevant
experience and distinguished leadership track records in the
biotech industry, all of which will be extremely valuable to Cidara
as we advance the rezafungin Phase 3 program and expand our
Cloudbreak immunotherapy platform,” said Jeffrey Stein, Ph.D.,
president and chief executive officer of Cidara. “I am confident
that Jamie’s diverse background in finance and experience on Wall
Street, as well as Jessica’s breadth of legal experience in
clinical development through to commercialization, will be
tremendous assets to our company.”
Prior to joining Cidara, Levine held senior executive and Board
roles at two biotechnology companies, Sapphire Energy and Verenium
Corporation, both of which were focused on the development,
manufacture and sale of products for the human and animal nutrition
markets. Previously, Levine was a managing director in the
investment banking division of Goldman Sachs & Co. in both New
York and London, where he spent 11 years focused on serving clients
in the healthcare and energy industries.
Levine holds a Master of Business Administration degree from the
Wharton School of the University of Pennsylvania and a Bachelor of
Arts degree in Economics from Brandeis University.
Oien formerly served as vice president, compliance at Otonomy,
Inc., where she developed and oversaw the commercial compliance
program and was the legal lead for the commercial business. She
served in similar roles at Pernix Therapeutics, Somaxon
Pharmaceuticals, Inc. and Verus Pharmaceuticals. She provided legal
consulting services for a robust clientele of early-stage biotech
companies including legal support for numerous collaborations, and
research and development programs. Oien also served as senior
director, legal affairs at Elan Corporation. She began her legal
career as outside corporate counsel at national law firms including
tenures at Brobeck, Phleger & Harrison and Millbank, Tweed,
Hadley & McCloy.
Oien holds a Juris Doctorate degree from Loyola Law School and a
Bachelor of Arts degree in Economics and Political Science from
North Dakota State University.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on
developing new anti-infectives that have the potential to transform
the standard of care and save or improve patients’ lives. The
company is currently advancing its novel echinocandin antifungal,
rezafungin acetate, in a Phase 3 clinical trial in the treatment of
candidemia and invasive candidiasis, and plans to initiate a second
Phase 3 trial in the prophylaxis of invasive fungal infections in
patients undergoing blood and marrow transplantation. Rezafungin
has improved pharmacokinetics compared to existing echinocandins
and the potential for expanded utility across patient settings. It
is the only once-weekly product candidate in development for the
treatment and prevention of life-threatening invasive fungal
infections. Cidara also is leveraging its novel Cloudbreak™
platform to develop antibody-drug conjugates for the treatment of
serious viral and Gram-negative bacterial infections. Cloudbreak is
the first immunotherapy discovery platform designed specifically to
create compounds that directly kill pathogens and also direct a
patient’s immune cells to attack and eliminate bacterial, fungal or
viral pathogens. Cidara is headquartered in San Diego, California.
For more information, please visit www.cidara.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181203005057/en/
MEDIA CONTACT:Christy CurranSam Brown
Inc.615-414-8668ChristyCurran@sambrown.com
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Sep 2023 to Sep 2024